Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury

paythelady.612 shared this article with you from Inoreader Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Feb 26;9(6):1284-1292. doi: 10.12998/wjcc.v9.i6.1284. ABSTRACT BACKGROUND: Acute kidney injury (AKI) is a sudden or rapid decline in the filtration function of the kidneys which is marked by increased serum creatinine or blood urea nitrogen. AIM: To examine the value of alprostadil-assisted continuous venous-venous hemofiltration (CVVH) in the treatment of severe AKI in severely ill patients. METHODS: This was a retrospective study and the inclusion criteria were as follows: (1) Age of patients (≥ 18 years); (2) Admission to intensive care unit due to non-renal primary disease, APACHE II score (≥ 18 points); (3) The diagnostic criteria of AKI guidelines were formulated with reference to the Global Organization for the Improvement of Prognosis in Kidney Diseases, with AKI grades of II-III; (4) All patients were treated with CVVH; and (5) Complete basic data were obtained for all patients. R ESULTS: The clinical effect of alprostadil administered in the treatment group was better than that observed in the control group (P < 0.05). The urine output of patients in the alprostadil group returned to normal time (9.1 ± 2.0 d) and was lower than that in the control group (10.6 ± 2.5 d), the difference was statistically significant (P < 0.05); adverse reactions occurred in the alprostadil group compared with the control group, but the difference was not statistically significant (P > 0.05). CONCLUSION: Alprostadil-assisted CVVH in the treatment of severely ill patients with AKI can effectively improve the renal resistance index and partial pressure of urine oxygen, and has a positive effect on improving renal function. PMID:33644195 | PMC:PMC7896675 | DOI:10.12998/wjcc.v9.i6.1284 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.